en Internal Internal Original Article Original Article <div> <div> <div id="_com_2" uage="JavaScript"><span style="font-size:14px;"><span style="font-family:Times New Roman;"><span style="color:#0000ff;"><strong><em>Background</em></strong><em>:</em> </span>It has been suggested that curcumin may be useful in diseases with cognitive dysfunction because it slows the progression and leads to the improvement of cognitive functions. In this study, the protective effects of curcumin on scopolamine-induced rat models of cognitive impairment were evaluated.<br> <span style="color:#0000ff;"><strong><em>Methods</em></strong><em>:</em> </span>21 male Wistar Albino rats, 1 year old, 200&plusmn;25 grams, were included in the study. They were divided into three groups (n: 7 in each group); the untreated control group, scopolamine group, and the group treated with curcumin and then exposed to scopolamine. Animals were evaluated for behavioral tasks with the Morris Water Maze test. Interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), total oxidative status (TOS), and total antioxidative status (TAS) were measured in hippocampal tissues. CRP levels were measured in serum specimens.<br> <span style="color:#0000ff;"><strong><em>Results</em></strong><em>:</em></span> We found that the length to reach the platform was the highest in the scopolamine group, and the lowest in the curcumin group (p<0.001). Time to reach the platform was the longest in the scopolamine group, and the shortest in the curcumin group (P=0.002). The length to reach the platform was the highest in the scopolamine group, and the lowest in the control group in the probe test (p<0.001). IL-6 levels were higher in the scopolamine group than the curcumin group (P=0.017) and the control group (P=0.005).<br> <span style="color:#0000ff;"><strong><em>Conclusion</em></strong><em>:</em></span> We revealed that curcumin provides a protective effect on scopolamine-induced cognitive impairment mimicking Alzheimer&#39;s disease.&nbsp; The use of curcumin for the protection of cognition in individuals at risk of developing AD may be considered.</span></span></div> </div> </div> <gdiv></gdiv> curcumin, scopolamine, Alzheimer’s disease, dementia, Morris Water Maze, inflammation 16 22 http://caspjim.com/browse.php?a_code=A-10-2026-1&slc_lang=en&sid=1 Guzin Cakmak drguzincakmak@gmail.com 100319475328460033276 100319475328460033276 Yes Gaziantep University, Faculty of Medicine, Department of Internal Medicine, Division of Geriatric Medicine, Gaziantep, Turkey Davut Sinan Kaplan davutsinankaplan@hotmail.com 100319475328460033277 100319475328460033277 No Gaziantep University, Faculty of Medicine, Department of Physiology, Gaziantep, Turkey Caner Yildirim caneryildirim27@gmail.com 100319475328460033278 100319475328460033278 No Gaziantep University, Faculty of Medicine, Department of Physiology, Gaziantep, Turkey Hasan Ulusal hasan_ulusal@hotmail.com 100319475328460033279 100319475328460033279 No Gaziantep University, Faculty of Medicine, Department of Biochemistry, Gaziantep, Turkey Mehmet Tarakcioglu tarakcioglum@gmail.com 100319475328460033280 100319475328460033280 No Gaziantep University, Faculty of Medicine, Department of Biochemistry, Gaziantep, Turkey Zeynel Abidin Öztürk zaodr79@yahoo.com 100319475328460033281 100319475328460033281 No Gaziantep University, Faculty of Medicine, Department of Internal Medicine, Division of Geriatric Medicine, Gaziantep, Turkey